dr. esserman gives an overview of the i-spy 2 trial
Published 10 years ago • 259 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
0:46
dr. esserman discusses the i-spy 2 trial
-
0:58
dr. esserman discusses the i-spy 2 trial in breast cancer
-
1:56
dr. esserman on the elements of the i-spy 2 trial in breast cancer
-
1:06
dr. esserman on the basis for the i-spy 2 trial in breast cancer
-
0:14
copy of dr. esserman discusses the i-spy 2 trial in breast cancer
-
0:18
copy of dr. esserman on the elements of the i-spy 2 trial in breast cancer
-
31:38
accelerating knowledge turns: the i-spy model and drug development - laura esserman
-
1:43
dr. esserman on the background of the i-spy 1 trial
-
19:27
relational intelligence in healthcare | dr. laura esserman, kerena saltzman | wisdom 2.0 2017
-
1:29:31
ucsf bay area breast cancer forum: "updates from san antonio breast cancer symposium 2023"
-
53:08
dr. daniel amen | brain spect imaging - psychiatry's tool to save lives
-
1:25
meredith buxton on i-spy 2 trial for her2 breast cancer
-
31:53
i-spy 2 and other platform trials
-
12:53
explanatory video about the i-spy 2 breast cancer clinical trial
-
1:46
i-spy 2: advancing outcomes high-risk breast cancer through adapting therapies
-
38:19
i-spy clinical trials: an interview with dr. laura esserman
-
1:22
dr. pusztai on rationale for the i-spy 2 trial with durvalumab/olaparib combo in her2- breast cancer
-
0:48
meredith buxton discusses the i-spy 2 trial
-
9:17
i-spy 2: durvalumab in combination with olaparib and paclitaxel in high-risk her2 negative stage...
-
2:01
i-spy 2 clinical trial for patients with stage 2 or 3 breast cancer
-
26:51
reinventing clinical trials with laura esserman
-
16:43
gs4 02 analysis of clinical outcomes and expression-based immune signatures by race in the i-spy 2